New chief medical officer for STORM Therapeutics

, , , ,

STORM Therapeutics, a biotechnology company focused on the discovery and development of small molecule therapies modulating RNA epigenetics, has appointed Dr. Josefin-Beate Holz as clinical advisor and chief medical officer.

“STORM is the world leading company tackling disease through modulating RNA modifying enzymes,” Dr. Holz says. “I am very pleased to support STORM in the planning of the clinical development of its METTL3i and exciting earlier-stage programs.” 

Dr. Holz has more than 25 years’ experience in pharmaceutical drug development in Europe and North America. She has held executive managerial positions at international pharmaceutical and biotech companies Ablynx, GPC-Biotech, Gilead Sciences, Bristol-Myers Squibb, and LEO Pharma. Dr. Holz has worked on more than 50 disease targets at various stages of clinical validation across oncology, immunology, and other indications.

According to Dr. Keith Blundy, CEO of STORM Therapeutics, “We are pleased to welcome Josefin to STORM. This is an exciting time as we accelerate the development of our lead program, the first-in-class METTL3 inhibitor, into IND enabling studies and clinical trials. Josefin brings a wealth of knowledge and experience in clinical research and has an excellent track record in the development of numerous molecular entities with novel mechanisms of action. Her experience will also add value to our pipeline of earlier programs, particularly as we advance a second program towards the clinic and apply our platform to new therapeutic areas beyond oncology.”

Dr. Holz is a medical advisor to the European Commission and is a member of various medical associations such as ASCO, ESMO, and SITC. She provides clinical advice and part-time CMO support for SMEs and biotech companies. Dr. Holz received her PhD in Hematology Oncology from the University Marburg, Germany in 1995.